The Lupus Research Alliance established Lupus Therapeutics in 2018 to support the clinical research of potential new treatments for lupus. With this addition, the Lupus Research Alliance is the only organization focused on the complete spectrum of lupus research from accelerating basic discoveries in the lab through clinical trials testing new therapies.
Many of the basic research breakthroughs supported by the Lupus Research Alliance have helped unravel the complexities of lupus and enabled the development of potential treatments and diagnostics now in clinical studies. Lupus Therapeutics is actively supporting several clinical studies for potential new therapies through its Lupus Clinical Investigators Network (LuCIN). Lupus Therapeutics created and oversees LuCIN, a North America-based lupus clinical trials network of 57 top academic research medical centers.
Lupus Therapeutics also offers its expertise combined with that of the Lupus Research Alliance to support academic, nonprofit and biotech and pharmaceutical organizations as they plan, initiate and manage clinical research.
In addition, Lupus Therapeutics is piloting the first peer-to-peer clinical trials education program, Patient Advocates for Lupus Studies or PALS. Created by Lupus Therapeutics and the Lupus Research Alliance, PALS aims to improve clinical research awareness, knowledge and enrollment, with a specific focus on making sure diverse populations at greatest risk for lupus are well represented in studies.
If you are interested in participating in clinical research, please speak with your physician and learn more about trials that might be right for you at the Lupus Research Alliance’s dedicated clinical research website, lupustrials.org.
Learn more about how Lupus Therapeutics can support your organization’s clinical research efforts.
